ProMIS Neurosciences Inc.

ProMIS Neurosciences develops therapeutic antibodies and vaccines targeting neurodegenerative and protein-misfolding disorders. Using its proprietary EpiSelect computational platform, the company predicts conformational disease-specific epitopes to generate humanized monoclonal antibodies and intrabodies that selectively neutralize neurotoxic misfolded proteins without disrupting healthy counterparts. Its pipeline includes PMN310, an antibody candidate undergoing clinical evaluation for Alzheimer’s disease designed to avoid monomer distraction and vascular plaque binding, alongside preclinical programs such as PMN267 for amyotrophic lateral sclerosis and frontotemporal lobar degeneration, and therapeutic candidates directed against alpha-synuclein for synucleinopathies.

The company conducts clinical development activities across multiple regions, having completed patient enrollment for its Phase 1b PRECISE-AD clinical study across 21 active clinical trial sites located in the United States. Preclinical research models and collaborative studies for its drug development programs have taken place in France, Belgium, and the United States. The company acquired technology licensing rights from the University of British Columbia, while the text does not disclose corporate headquarters or commercial facilities.

Summary of the business section of ProMIS Neurosciences's latest annual report, written by StockData.

“It is estimated there are currently 30,000 people in the United States and 450,000 people worldwide, suffering from ALS, with approximately 5,000 new cases arising in the United States annually.”